Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3β

Biology Open

Volumn 3, Issue 1, 2014, Pages 1-11

  Povellato, Giulia ^a   Tuxworth, Richard I ^a,b   Hanger, Diane P ^c   Tear, Guy ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Drosophila; GSK3b; Phosphorylation; Tau

Indexed keywords

EID: 84979083907     PISSN: None     EISSN: 20466390     Source Type: Journal    
DOI: 10.1242/bio.20136692     Document Type: Article

References (76)

1. Arendt, T., Stieler, J., Strijkstra, A. M., Hut, R. A., Rüdiger, J., Van der Zee, E. A., Harkany, T., Holzer, M. and Härtig, W. (2003). Reversible paired helical filamentlike phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J. Neurosci. 23, 6972-6981.
2. Ballatore, C., Lee, V. M. and Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672.
3. Bonda, D. J., Castellani, R. J., Zhu, X., Nunomura, A., Lee, H. G., Perry, G. and Smith, M. A. (2011). A novel perspective on tau in Alzheimer's disease. Curr. Alzheimer Res. 8, 639-642.
4. Brunden, K. R., Trojanowski, J. Q. and Lee, V. M. (2009). Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 8, 783-793.
5. Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A. and Hof, P. R. (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130.
6. Buée, L., Troquier, L., Burnouf, S., Belarbi, K., Van der Jeugd, A., Ahmed, T., Fernandez-Gomez, F., Caillierez, R., Grosjean, M. E., Begard, S. et al. (2010). From tau phosphorylation to tau aggregation: what about neuronal death? Biochem. Soc. Trans. 38, 967-972.
7. Bunker, J. M., Kamath, K., Wilson, L., Jordan, M. A. and Feinstein, S. C. (2006). FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. J. Biol. Chem. 281, 11856-11863.
8. Castellani, R. J., Nunomura, A., Lee, H. G., Perry, G. and Smith, M. A. (2008). Phosphorylated tau: toxic, protective, or none of the above. J. Alzheimers Dis. 14, 377-383.
9. Chatterjee, S., Sang, T. K., Lawless, G. M. and Jackson, G. R. (2009). Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum. Mol. Genet. 18, 164-177.
10. Chau, K. W., Chan, W. Y., Shaw, P. C. and Chan, H. Y. (2006). Biochemical investigation of Tau protein phosphorylation status and its solubility properties in Drosophila. Biochem. Biophys. Res. Commun. 346, 150-159.
11. Churcher, I. (2006). Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 6, 579-595.
12. Cowan, C. M., Bossing, T., Page, A., Shepherd, D. and Mudher, A. (2010). Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol. 120, 593-604.
13. Delobel, P., Flament, S., Hamdane, M., Jakes, R., Rousseau, A., Delacourte, A., Vilain, J. P., Goedert, M. and Buée, L. (2002). Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation. J. Biol. Chem. 277, 9199-9205.
14. Doble, B. W. and Woodgett, J. R. (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186.
15. Feijoo, C., Campbell, D. G., Jakes, R., Goedert, M. and Cuenda, A. (2005). Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. J. Cell Sci. 118, 397-408.
16. Feuillette, S., Miguel, L., Frébourg, T., Campion, D. and Lecourtois, M. (2010). Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. J. Neurochem. 113, 895-903.
17. Ghoshal, N., Smiley, J. F., DeMaggio, A. J., Hoekstra, M. F., Cochran, E. J., Binder, L. I. and Kuret, J. (1999). A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. Am. J. Pathol. 155, 1163-1172.
18. Gistelinck, M., Lambert, J. C., Callaerts, P., Dermaut, B. and Dourlen, P. (2012). Drosophila models of tauopathies: what have we learned? Int. J. Alzheimers Dis. 2012, 970980.
19. Gómez-Ramos, A., Díaz-Nido, J., Smith, M. A., Perry, G. and Avila, J. (2003). Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J. Neurosci. Res. 71, 863-870.
20. Gordon-Krajcer, W., Kozniewska, E., Lazarewicz, J. W. and Ksiezak-Reding, H. (2007). Differential changes in phosphorylation of tau at PHF-1 and 12E8 epitopes during brain ischemia and reperfusion in gerbils. Neurochem. Res. 32, 729-737.
21. Groth, A. C., Fish, M., Nusse, R. and Calos, M. P. (2004). Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31. Genetics 166, 1775-1782.
22. Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P. and Anderton, B. H. (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147, 58-62.
23. Hanger, D. P., Betts, J. C., Loviny, T. L., Blackstock, W. P. and Anderton, B. H. (1998). New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71, 2465-2476.
24. Hanger, D. P., Byers, H. L., Wray, S., Leung, K. Y., Saxton, M. J., Seereeram, A., Reynolds, C. H., Ward, M. A. and Anderton, B. H. (2007). Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 282, 23645-23654.
25. Hanger, D. P., Anderton, B. H. and Noble, W. (2009). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119.
26. Heutink, P. (2000). Untangling tau-related dementia. Hum. Mol. Genet. 9, 979-986.
27. Hirata-Fukae, C., Li, H. F., Ma, L., Hoe, H. S., Rebeck, G. W., Aisen, P. S. and Matsuoka, Y. (2009). Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo. Neurosci. Lett. 450, 51-55.
28. Huang, H. C. and Klein, P. S. (2006). Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Curr. Drug Targets 7, 1389-1397.
29. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A. et al. (1998). Association of missense and 59-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
30. Ingelsson, M., Ramasamy, K., Russ, C., Freeman, S. H., Orne, J., Raju, S., Matsui, T., Growdon, J. H., Frosch, M. P., Ghetti, B. et al. (2007). Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol. 114, 471-479.
31. Iqbal, K., Liu, F., Gong, C. X., Alonso, A. C. and Grundke-Iqbal, I. (2009). Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 118, 53-69.
32. Ishihara, T., Zhang, B., Higuchi, M., Yoshiyama, Y., Trojanowski, J. Q. and Lee, V. M. (2001). Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am. J. Pathol. 158, 555-562.
33. Jackson, G. R., Wiedau-Pazos, M., Sang, T. K., Wagle, N., Brown, C. A., Massachi, S. and Geschwind, D. H. (2002). Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509-519.
34. Karsten, S. L., Sang, T. K., Gehman, L. T., Chatterjee, S., Liu, J., Lawless, G. M., Sengupta, S., Berry, R. W., Pomakian, J., Oh, H. S. et al. (2006). A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron 51, 549-560.
35. Khurana, V. (2008). Modeling tauopathy in the fruit fly Drosophila melanogaster. J. Alzheimers Dis. 15, 541-553.
36. Khurana, V., Lu, Y., Steinhilb, M. L., Oldham, S., Shulman, J. M. and Feany, M. B. (2006). TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr. Biol. 16, 230-241.
37. Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H. et al. (2007). The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum. Mol. Genet. 16, 15-23.
38. Kuret, J., Johnson, G. S., Cha, D., Christenson, E. R., DeMaggio, A. J. and Hoekstra, M. F. (1997). Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. J. Neurochem. 69, 2506-2515.
39. Lebouvier, T., Scales, T. M., Williamson, R., Noble, W., Duyckaerts, C., Hanger, D. P., Reynolds, C. H., Anderton, B. H. and Derkinderen, P. (2009). The microtubuleassociated protein tau is also phosphorylated on tyrosine. J. Alzheimers Dis. 18, 1-9.
40. Lee, V. M., Goedert, M. and Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159.
41. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X. et al. (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405.
42. Lindwall, G. and Cole, R. D. (1984). Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301-5305.
43. Liu, F., Liang, Z., Wegiel, J., Hwang, Y. W., Iqbal, K., Grundke-Iqbal, I., Ramakrishna, N. and Gong, C. X. (2008). Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 22, 3224-3233.
44. Lovestone, S., Reynolds, C. H., Latimer, D., Davis, D. R., Anderton, B. H., Gallo, J. M., Hanger, D., Mulot, S., Marquardt, B., Stabel, S. et al. (1994). Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077-1086.
45. Lucas, J. J., Hernández, F., Gómez-Ramos, P., Morán, M. A., Hen, R. and Avila, J. (2001). Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
46. Mack, T. G., Dayanandan, R., Van Slegtenhorst, M., Whone, A., Hutton, M., Lovestone, S. and Anderton, B. H. (2001). Tau proteins with frontotemporal dementia-17 mutations have both altered expression levels and phosphorylation profiles in differentiated neuroblastoma cells. Neuroscience 108, 701-712.
47. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. and Kivipelto, M. (2010). Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702-716.
48. Martin, L., Latypova, X. and Terro, F. (2011). Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem. Int. 58, 458-471.
49. Mazanetz, M. P. and Fischer, P. M. (2007). Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6, 464-479.
50. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Watanabe, A., Titani, K. and Ihara, Y. (1995). Hyperphosphorylation of tau in PHF. Neurobiol. Aging 16, 365-371, discussion 371-380.
51. Morris, M., Maeda, S., Vossel, K. and Mucke, L. (2011). The many faces of tau. Neuron 70, 410-426.
52. Mudher, A., Shepherd, D., Newman, T. A., Mildren, P., Jukes, J. P., Squire, A., Mears, A., Drummond, J. A., Berg, S., MacKay, D. et al. (2004). GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry 9, 522-530.
53. Muqit, M. M. and Feany, M. B. (2002). Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat. Rev. Neurosci. 3, 237-243.
54. Nishimura, I., Yang, Y. and Lu, B. (2004). PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116, 671-682.
55. Planel, E., Richter, K. E., Nolan, C. E., Finley, J. E., Liu, L., Wen, Y., Krishnamurthy, P., Herman, M., Wang, L., Schachter, J. B. et al. (2007). Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J. Neurosci. 27, 3090-3097.
56. Potter, C. J. and Luo, L. (2010). Splinkerette PCR for mapping transposable elements in Drosophila. PLoS ONE 5, e10168.
57. Ryoo, S. R., Jeong, H. K., Radnaabazar, C., Yoo, J. J., Cho, H. J., Lee, H. W., Kim, I. S., Cheon, Y. H., Ahn, Y. S., Chung, S. H. et al. (2007). DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem. 282, 34850-34857.
58. Sato, S., Tatebayashi, Y., Akagi, T., Chui, D. H., Murayama, M., Miyasaka, T., Planel, E., Tanemura, K., Sun, X., Hashikawa, T. et al. (2002). Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J. Biol. Chem. 277, 42060-42065.
59. Shulman, J. M. and Feany, M. B. (2003). Genetic modifiers of tauopathy in Drosophila. Genetics 165, 1233-1242.
60. Spradling, A. C. and Rubin, G. M. (1982). Transposition of cloned P elements into Drosophila germ line chromosomes. Science 218, 341-347.
61. Steinhilb, M. L., Dias-Santagata, D., Fulga, T. A., Felch, D. L. and Feany, M. B. (2007a). Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol. Biol. Cell 18, 5060-5068.
62. Steinhilb, M. L., Dias-Santagata, D., Mulkearns, E. E., Shulman, J. M., Biernat, J., Mandelkow, E. M. and Feany, M. B. (2007b). S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J. Neurosci. Res. 85, 1271-1278.
63. Talmat-Amar, Y., Arribat, Y., Redt-Clouet, C., Feuillette, S., Bougé, A. L., Lecourtois, M. and Parmentier, M. L. (2011). Important neuronal toxicity of microtubule-bound Tau in vivo in Drosophila. Hum. Mol. Genet. 20, 3738-3745.
64. Thies, E. and Mandelkow, E. M. (2007). Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci. 27, 2896-2907.
65. Tuxworth, R. I., Vivancos, V., O'Hare, M. B. and Tear, G. (2009). Interactions between the juvenile Batten disease gene, CLN3, and the Notch and JNK signalling pathways. Hum. Mol. Genet. 18, 667-678.
66. Wada, Y., Ishiguro, K., Itoh, T. J., Uchida, T., Hotani, H., Saito, T., Kishimoto, T. and Hisanaga, S. (1998). Microtubule-stimulated phosphorylation of tau at Ser202 and Thr205 by cdk5 decreases its microtubule nucleation activity. J. Biochem. 124, 738-746.
67. Wen, Y., Yang, S., Liu, R. and Simpkins, J. W. (2004). Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res. 1022, 30-38.
68. Wilson, C., Bellen, H. J. and Gehring, W. J. (1990). Position effects on eukaryotic gene expression. Annu. Rev. Cell Biol. 6, 679-714.
69. Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M. and Feany, M. B. (2001). Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711-714.
70. Woods, Y. L., Rena, G., Morrice, N., Barthel, A., Becker, W., Guo, S., Unterman, T. G. and Cohen, P. (2001). The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem. J. 355, 597-607.
71. Wu, P. R., Tsai, P. I., Chen, G. C., Chou, H. J., Huang, Y. P., Chen, Y. H., Lin, M. Y., Kimchi, A., Chien, C. T. and Chen, R. H. (2011). DAPK activates MARK1/ 2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity. Cell Death Differ. 18, 1507-1520.
72. Yu, Y., Run, X., Liang, Z., Li, Y., Liu, F., Liu, Y., Iqbal, K., Grundke-Iqbal, I. and Gong, C. X. (2009). Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J. Neurochem. 108, 1480-1494.
73. Zambrano, C. A., Egaña, J. T., Núñez, M. T., Maccioni, R. B. and González-Billault, C. (2004). Oxidative stress promotes tau dephosphorylation in neuronal cells: the roles of cdk5 and PP1. Free Radic. Biol. Med. 36, 1393-1402.
74. Zeng, X., Tamai, K., Doble, B., Li, S., Huang, H., Habas, R., Okamura, H., Woodgett, J. and He, X. (2005). A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438, 873-877.
75. Zhang, B., Higuchi, M., Yoshiyama, Y., Ishihara, T., Forman, M. S., Martinez, D., Joyce, S., Trojanowski, J. Q. and Lee, V. M. (2004). Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 24, 4657-4667.
76. Zhukareva, V., Shah, K., Uryu, K., Braak, H., Del Tredici, K., Sundarraj, S., Clark, C., Trojanowski, J. Q. and Lee, V. M. (2002). Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease: a comparative study. Am. J. Pathol. 161, 1135-1141.